Entera Bio (NASDAQ:ENTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Entera Bio (NASDAQ:ENTX) to a sell rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $1.80 on Friday. The firm has a fifty day moving average price of $2.38 and a two-hundred day moving average price of $2.11. The company has a market cap of $82.55 million, a price-to-earnings ratio of -7.20 and a beta of 1.71. Entera Bio has a one year low of $1.50 and a one year high of $3.22.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 67.56%. Equities research analysts expect that Entera Bio will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

Large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. purchased a new position in shares of Entera Bio in the 2nd quarter worth about $268,000. Citadel Advisors LLC lifted its position in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after buying an additional 28,322 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in Entera Bio by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock worth $747,000 after buying an additional 25,900 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after buying an additional 6,310 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.